IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know

Zacks
Открыть на Zacks
IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know

IQVIA Holdings IQV shares have soared 58.8% over the past six months, beating the industry’s 30.9% and the Zacks S&P 500 Composite's marginal return.

6-Month Share Price Performance

Zacks Investment ResearchImage Source: Zacks Investment Research

Let us delve deeper into the factors behind the company’s solid price performance.

Clinical Research & Commercial Solutions Drives Growth: Rising clinical research activity and stronger outsourcing demand benefit the Research & Development (R&D) Solutions. In the third quarter of 2026, this segment’s revenues moved up 8.7% year over year, with organic growth approaching the 7% mark. Net new bookings climbed 15% year over year, marking the strongest quarterly bookings in four years. IQV’s growth momentum is sustained on the back of strong emerging biopharma funding, increasing clinical trial activity and higher win rates.

The company’s Commercial Solutions segment benefits from the rising demand for healthcare information, analytics and consulting services. In the third quarter of 2026, this segment’s revenues gained 6.9% year over year, accompanied by an organic growth of 4%. Record sales pipelines and improving customer decision timelines supported the segment’s strong revenue growth for four consecutive quarters.

Competitive Edge From AI Adoption: IQVIA’s widening AI portfolio is improving clinical trial execution, commercial decision-making and operational prowess. The company has deployed 415 AI agents, highlighting the rising adoption of its agentic solutions. IQV is able to identify patients faster, optimize trial designs and cut down development timelines. For instance, the company’s AI-enabled modeling solutions stripped down a pharma client’s clinical development timeline by nine months.

Operational Efficiency Strengthens Bottom Line: IQVIA’s profitability is supported by its productivity initiatives, cost-management measures and AI-driven automation. In the third quarter of 2026, adjusted EBITDA moved up 8.7% year over year with its margins gaining 20 basis points (bps). Operational enhancements contributed 80 bps to the underlying margin expansion. Strong operational execution led to an 11.3% year-over-year jump in the bottom line. Persistent automation and productivity improvements should support margin expansion.

Zacks Rank & Stocks to Consider

IQV currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader Zacks Medical sector are Acadia Healthcare ACHC and Alector ALEC, currently sporting a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy), respectively. You can see the complete list of today’s Zacks #1 Rank stocks here.

Acadia Healthcare has a long-term earnings growth expectation of 4.6%. ACHC delivered a trailing four-quarter earnings surprise of 52.8%, on average.

Alector has a long-term earnings growth expectation of 32.9%. EVTC delivered a trailing four-quarter earnings surprise of 162%, on average.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
IQVIA Holdings Inc. (IQV): Free Stock Analysis Report
 
Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report
 
Alector, Inc. (ALEC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research